Active substanceHydrochlorothiazide + LosartanHydrochlorothiazide + Losartan
Similar drugsTo uncover
  • Blocktran® GT
    pills inwards 
  • BIOKOM, CJSC     Russia
  • TAD Pharma GmbH     Germany
  • AKRIKHIN HFK, JSC     Russia
  • Gizaar®
    pills inwards 
    Merck Sharp and Doum B.V.     Netherlands
  • GISAAR® Forte
    pills inwards 
    Merck Sharp and Doum B.V.     Netherlands
  • Lopaz plus
    pills inwards 
    Zentiva c.s.     Czech Republic
  • Lozarel® Plus
    pills inwards 
    Sandoz d.     Slovenia
  • Losartan H
    pills inwards 
    ATOLL, LLC     Russia
  • Losartan-N Canon
    pills inwards 
  • Lorista® H
    pills inwards 
  • Lorista® N 100
    pills inwards 
  • Lorista® ND
    pills inwards 
  • Prezartan® H
    pills inwards 
  • Simartan-N
    pills inwards 
  • Dosage form: & nbspfilm-coated tablets
    Composition:

    For 1 tablet:

    Core

    Active substances: hydrochlorothiazide 12.50 mg, potassium losartan 50.00 mg.

    Excipients: pregelatinized starch 34.92 mg, microcrystalline cellulose 87.70 mg, lactose monohydrate 63.13 mg, magnesium stearate 1.75 mg.

    Film Sheath: hypromellose 5.00 mg, macrogol 4000 0.50 mg, dye quinoline yellow (E104) 0.11 mg, titanium dioxide (E171) 1.39 mg, talc 0.50 mg.

    Description:Oval, slightly biconvex tablets, covered with a film coating from yellow to yellow with a greenish tint of color, with a risk on one side.
    Pharmacotherapeutic group:Hypotensive combined agent (angiotensin II receptor antagonist + diuretic)
    ATX: & nbsp

    C.09.D.A.01   Losartan in combination with diuretics

    Pharmacodynamics:

    Hydrochlorothiazide / losartan

    Lorista® H is a combined preparation, the components of which have an additive hypotensive effect and cause a more pronounced decrease in blood pressure (BP) in comparison with their separate use. Due to diuretic action hydrochlorothiazide increases blood plasma renin activity, aldosterone secretion, reduces serum potassium content, and increases the concentration of angiotensin II in blood plasma. Losartan blocks the physiological effects of angiotensin II and by inhibiting the secretion of aldosterone can neutralize the loss of potassium ions caused by a diuretic. Losartan has a uricosuric effect. Hydrochlorothiazide causes a moderate increase in the concentration of uric acid, with the use of losartan concomitantly with hydrochlorothiazide, hyperuricemia caused by a diuretic decreases. Hypotensive effect combination hydrochlorothiazide / losartan persists for 24 hours. Despite a significant reduction in blood pressure, the use of combination hydrochlorothiazide / losartan has no clinically significant effect on the heart rate (heart rate). Combination hydrochlorothiazide / losartan is effective in men and women, as well as in patients younger (less than 65 years) and elderly (from 65 years and older) age.

    Losartan

    Losartan is an angiotensin II receptor antagonist (ARA II) for oral administration, non-protein nature. Angiotensin II is a potent vasoconstrictor and the main hormone of the renin-angiotensin-aldosterone system (RAAS). Angiotensin II binds to AT1receptors that are found in many tissues (eg, smooth vascular muscles, adrenal glands, kidneys and myocardium) and mediate the various biological effects of angiotensin II, including vasoconstriction and aldosterone release.In addition, angiotensin II stimulates the proliferation of smooth muscle cells. Losartan selectively blocks AT1-receptors. In vivo and in vitro losartan and its biologically active carboxylic metabolite (EXP-3174) block all physiologically significant effects of angiotensin II on AT1-receptors regardless of the pathway of its synthesis. Losartan does not possess agonism and does not block other hormonal receptors or ion channels that are important in the regulation of the cardiovascular system. Losartan does not inhibit the activity of angiotensin-converting enzyme (ACE) (kinase II), an enzyme that participates in the metabolism of bradykinin. Accordingly, it does not cause an increase in the frequency undesirable effects mediated by bradykinin.

    Losartan indirectly causes AT activation2-receptors by increasing the concentration of angiotensin II in the blood plasma.

    Suppression of regulation of renin secretion by angiotensin II by the mechanism of "negative feedback" in the treatment of losartan causes an increase in renin activity of blood plasma, which leads to an increase in the concentration of angiotensin II in blood plasma.However, the hypotensive effect and suppression of aldosterone secretion persist, indicating an effective blockade of the angiotensin II receptors. After abolition of losartan, plasma renin activity and angiotensin II concentration decrease to baseline values ​​within 3-x days. Losartan and its main active metabolite have a significantly higher affinity for AT1-receptors in comparison with AT2receptors. The active metabolite is superior losartan by activity in 10-40 time. The frequency of cough development is comparable with the use of losartan or hydrochlorothiazide and is significantly lower than with the use of an ACE inhibitor. In patients with hypertension, proteinuria and without diabetes, treatment with losartan significantly reduces proteinuria, albumin excretion and immunoglobulin G (IgG). Losartan supports glomerular filtration and reduces the filtration fraction. Losartan reduces the serum concentration of uric acid (usually less than 0.4 mg / dL) throughout the therapy. Losartan does not have an effect on vegetative reflexes and does not affect the concentration of noradrenaline in the blood plasma.

    In patients with left ventricular failure losartan in doses of 25 mg and 50 mg has positive hemodynamic and neurohumoral effects, characterized by an increase in the cardiac index and a decrease in the wedging pressure of the pulmonary capillaries, the common peripheral vascular resistance (OPSS), mean blood pressure and heart rate and a decrease in plasma concentrations of aldosterone and norepinephrine. Risk of development Arterial hypotension in patients with heart failure depends on the dose of losartan.

    The use of losartan once a day in patients with mild and moderate essential hypertension causes a significant reduction in systolic and diastolic blood pressure. The hypotensive effect lasts for 24 hours while maintaining the natural circadian BP rhythm. The degree of BP reduction at the end of the dosing interval is 70-80% compared to the hypotensive effect 5-6 hours after the administration of losartan. Losartan is effective in men and women, as well as in elderly patients (65 and over) and younger patients (under 65 years of age). The abolition of losartan in patients with arterial hypertension does not lead to a sharp increase in blood pressure (there is no "withdrawal" syndrome). Losartan does not have a clinically significant effect on heart rate.

    Hydrochlorothiazide

    The thiazide diuretic, whose mechanism of hypotensive action is not definitively established. Thiazides alter the reabsorption of electrolytes in the distal nephron and increase the excretion of sodium and chlorine ions approximately equally. The diuretic effect of hydrochlorothiazide leads to a decrease in the volume of circulating blood (BCC), an increase in plasma renin activity and aldosterone secretion, which leads to an increase in excretion of potassium and bicarbonate ions by the kidneys and a decrease in serum potassium content. The relationship between renin and aldosterone is mediated angiotensin II, so the simultaneous use of ARA II suppresses the loss of potassium ions when treated with thiazide diuretics.

    After oral administration, diuretic the effect occurs after 2 hours, reaches a maximum in about 4 hours and persists for 6-12 hours, the hypotensive effect persists for 24 hours.

    Pharmacokinetics:

    The pharmacokinetics of losartan and hydrochlorothiazide at simultaneous reception does not differ from that at their separate application.

    Suction

    Losartan: after oral administration losartan well absorbed and metabolized when "primary pass through the liver with the formation of an active carboxyl metabolite (EXP-3174) and inactive metabolites.The systemic bioavailability is approximately 33% .The average maximum concentrations (Cmax) in the blood plasma of losartan and its active metabolite are achieved after 1 hour and 3-4 hours, respectively.

    Hydrochlorothiazide

    After oral intake of hydrochlorothiazide is 60-80%. FROMmax hydrochlorothiazide in blood plasma is achieved after 1-5 h after ingestion.

    Distribution

    Losartan: more than 99% of losartan and EXP-3174 binds to blood plasma proteins, mainly albumin. The volume of distribution of losartan is 34 liters. Very poorly penetrates the blood-brain barrier. Hydrochlorothiazide: the connection with plasma proteins is 64%; penetrates the placenta, but not through the blood-brain barrier and is excreted in breast milk.

    Biotransformation

    Losartan: approximately 14% of the dose of losartan administered intravenously or is metabolized to form an active metabolite. After oral administration and / or intravenous administration 14C-losartan potassium, the circulating radioactivity of blood plasma, was mainly determined by losartan and its active metabolite.In addition to the active metabolite, inactive metabolites are formed, including the two main metabolites formed by the hydroxylation of the butyl group of the chain, and the non-basic metabolite - N-2tetrazole glucuronide. The intake of the drug with food does not have a clinically significant effect on its serum concentrations. Hydrochlorothiazide not metabolized.

    Excretion

    Losartan: the plasma clearance of losartan and its active metabolite is 600 ml / min and 50 ml / min, respectively; The renal clearance of losartan and its active metabolite is 74 ml / min and 26 ml / min, respectively. After oral administration, only about 4% of the dose taken is excreted unchanged by the kidneys and about 6% - in the form of an active metabolite. Pharmacokinetic The parameters of losartan and its active metabolite when taken orally (in doses up to 200 mg) are linear.

    The half-life (T1/2) in the terminal phase of losartan and the active metabolite is 2 hours and 6-9 hours, respectively. Cumulation of losartan and its active metabolite when administered at a dose of 100 mg once a day is not. It is mainly intestines with bile (58%), kidneys - 35%.

    Hydrochlorothiazide: quickly excreted through the kidneys. T1/2 is 5.6 - 14.8 hours. About 61% of the ingested dose is excreted unchanged.

    Pharmacokinetics of individual patient groups

    Hydrochlorothiazide / losartan

    Plasma concentrations of losartan and its active metabolite and hydrochlorothiazide y elderly patients with arterial hypertension did not differ significantly from those in young patients.

    Losartan

    Patients with mild and moderate alcoholic liver cirrhosis after oral administration of losartan, concentration of losartan and active metabolite in blood plasma were 5 and 1.7 times higher, than in young male volunteers sex, respectively. Losartan and its active metabolite are not removed during hemodialysis.

    Indications:- Arterial hypertension (patients who are shown combined therapy).

    - Reducing the risk of cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy.

    Contraindications:

    - Hypersensitivity to losartan, hydrochlorothiazide and other derivatives of sulfonamide, as well as to auxiliary substances.

    - Anuria, severe renal failure (creatinine clearance (CK) less than 30 ml / min.).

    - Severe hepatic insufficiency (more than 9 on the Child-Pugh scale), cholestasis and obstructive diseases of the biliary tract.

    - Simultaneous use with aliekirei in patients with diabetes mellitus or renal dysfunction (CC less than 60 ml / min).

    - Age to 18 years (efficacy and safety of use not established).

    - Hypokalemia or hypercalcaemia, resistant to therapy.

    - Refractory hyponatremia.

    - Pregnancy, the period of breastfeeding.

    - Deficiency of lactase, lactose intolerance, glucose-galactose malabsorption syndrome, since loritis is included in the composition of Lorist® H.

    Carefully:
    Pronounced hyponatremia and / or conditions accompanied by a decrease in bcc (including diet with restriction of table salt, diarrhea, vomiting, high diuretic therapy), violation of water-electrolyte balance of blood, diabetes mellitus, renal failure (QC 30-50 ml / min), a malfunction of the liver of mild to moderate severity (less than 9 points on the Child-Pugh scale) without the phenomena of cholestasis in the anamnesis,Chronic heart failure (CHF) III-IV functional class NYHA classification, and other conditions associated with activation of the RAAS, bilateral renal artery stenosis or stenosis of the artery only kidney condition after kidney transplantation, primary aldosteronism, ischemic heart disease and cerebrovascular disease, ie. to An excessive decrease in blood pressure can lead to the development of myocardial infarction and stroke, stenosis of the aortic and / or mitral valve, hypertrophic obstructive cardiomyopathy (GOKMP), allergic history (if the patient has a history of angioneurotic edema when applied drugs, t. h. ACE inhibitors and ARA II and bronchial asthma, systemic lupus erythematosus, acute myopia and secondary angle-closure glaucoma acute, symptomatic gpperurikemiya / gout.
    Pregnancy and lactation:

    The use of ARA II in the first trimester of pregnancy is not recommended. The drug Lorista® N should not be used during pregnancy and in women planning a pregnancy. When planning pregnancy, it is recommended that the patient be transferred to alternative antihypertensive therapy, taking into account the safety profile.If pregnancy is confirmed, stop taking Lorist® H and, if necessary, transfer to alternative antihypertensive therapy. Lorista® H, as well as other agents having a direct effect on RAAS, can cause unwanted effects in the fetus (renal dysfunction, deceleration of ossification of the fetal bones, oligohydramnion) and neonatal toxic effects (renal failure, arterial hypotension, hyperkalemia). If nevertheless used the drug Lorist® H in the II-III trimesters of pregnancy, then it is necessary to perform ultrasound examination of the kidneys and bones of the fetal skull. Hydrochlorothiazide penetrates the placenta. With the use of thiazide diuretics in the II-III trimester of pregnancy, a decrease in uteroplacental blood flow, development of thrombocytopenia, jaundice, violation of water-electrolyte balance in the fetus or newborn. Hydrochlorothiazide should not be used for the treatment of gestosis in the second half of pregnancy (edema, hypertension or preeclampsia (nephropathy)) due to the risk of a reduction in bcc and a decrease in uteroplacental blood flow in the absence of a favorable effect on the course of the disease. Hydrochlorothiazide should not be used to treat essential hypertension in pregnant women, except in rare cases when it is not possible to use alternative agents.

    Newborns whose mothers took Lorista® H during pregnancy should be monitored, since the development of arterial hypertension in a newborn is possible.

    Breastfeeding period

    The drug Lorista® N is not recommended during lactation, since there is no experience of use. It is recommended to use other antihypertensive drugs taking into account the safety profile. It is not known whether losartan with breast milk. Hydrochlorothiazide penetrates into breast milk in small amounts. Thiazide diuretics in high doses cause intense diuresis, thereby suppressing lactation.

    Dosing and Administration:

    Inside, regardless of food intake, with plenty of water, once a day. The drug Lorista® N can be taken concomitantly with other antihypertensive drugs.

    Arterial hypertension

    The combination of hydrochlorothiazide / losartan is indicated in patients who do not receive adequate blood pressure control when administered hydrochlorothiazide or losartan separately.

    It is recommended to titrate the dose of losartan and hydrochlorothiazide before transferring the patient to therapy with Lorist® N. If necessary (with inadequate control of blood pressure), the issue of transferring the patient from therapy with Lorist® (losartan) on therapy with Lorista® N.

    The initial and maintenance dose is 1 tablet of Lorist® H (hydrochlorothiazide 12.5 mg and losartan 50 mg). The maximum hypotensive effect is achieved within 3 weeks of therapy. To achieve a more pronounced effect, it is possible to increase the dose of Lorist® N. The maximum daily dose is 2 tablets of Lorist® H once a day.

    Special patient groups:

    Patients with impaired renal function or who are on hemodialysis: in patients with moderate renal dysfunction (CK 30-50 ml / min) correction of the initial dose of the drug is not required. Losartan and hydrochlorothiazide is not recommended for patients on hemodialysis.

    Patients with low BCC: the initial dose of losartan is recommended to be 25 mg once a day. Before starting treatment with Lorist® H, you should cancel the diuretic, restore bcc and / or sodium ions.

    Elderly patients: dose adjustment is usually not required.

    Reducing the risk of cardiovascular morbidity and mortality in patients with hypertension and left ventricular hypertrophy

    The standard initial dose of losartan is 50 mg once a day. Patients who failed to achieve target BP levels when taking Losartan 50 mg / day require treatment by a combination of losartan with low doses of hydrochlorothiazide (12.5 mg). If necessary, increase the dose of losartan up to 100 mg / day simultaneously with hydrochlorothiazide at a dose of 12.5 mg / day, then - increase to 2 tablets of Lorista® H (total 25 mg hydrochlorothiazide and 100 mg losartan per day) once a day . If you need to further reduce blood pressure, you should add other antihypertensive drugs.
    Side effects:

    Classification of the frequency of development of side effects of the World Health Organization (WHO):

    Often ≥1/10

    often from ≥1 / 100 to <1/10

    infrequently from ≥1 / 1000 to <1/100

    rarely from ≥1 / 10000 to <1/1000

    very rarely <1/10000

    the frequency of the unknown can not be estimated from the available data. Undesirable reactions with the combination hydrochlorothiazide / losartan were observed earlier with and losartan and / or hydrochlorothiazide.

    Postmarketing application combinations hydrochlorothiazide / losartan

    Additional adverse reactions:

    From the digestive system:

    rarely: hepatitis.

    Laboratory data:

    rarely: hyperkalemia, increased activity of alanine aminotransferase (ALT).

    Undesirable reactions that occurred when used in monotherapy with losartan or hydrochlorothiazide and can be used with the combination hydrochlorothiazide / losartan:

    Losartan

    From the hematopoiesis:

    infrequently: anemia, purple Shenlaine-Henoch, ecchymosis, hemolysis;

    frequency unknown: thrombocytopenia.

    From the cardiovascular system:

    infrequently: marked decrease in blood pressure, Orthostatic hypotension, chest pain, angina pectoris, atrioventricular blockade (AV blockade) II degree, cerebral blood flow disorder, myocardial infarction (with excessive decrease in blood pressure), a feeling of "heartbeat", arrhythmia (atrial fibrillation, sinus bradycardia, tachycardia, ventricular tachycardia, ventricular fibrillation), vasculitis.

    From the sense organs:

    infrequently: vertigo, tinnitus, blurred vision, burning sensation / tingling sensation in the eyes, conjunctivitis, decreased visual acuity.

    From the digestive system:

    often: abdominal pain, nausea, diarrhea, dyspepsia;

    infrequent: constipation, pain in the teeth, dryness mucous membrane of the oral cavity, bloating stomach, gastritis, vomiting, obstruction intestines;

    frequency unknown: pancreatitis, abnormal liver function.

    Allergic reactions:

    rarely: hypersensitivity: anaphylactic reactions, angioedema, including edema larynx and pharynx causing obstruction of the airways and / or swelling of the face, lips, throat and / or tongue; the some angioedema patients edema was also noted in a history of treatment with other drugs, including ACE inhibitors.

    From the side of the locomotor system apparatus:

    often: muscle cramps, back pain, pain in the legs, myalgia;

    infrequently: pain in the hands, swelling of the joints, pain in the knees, musculoskeletal pain, pain in the shoulders, stiffness, arthralgia, arthritis, coxalgia, fibromyalgia, muscle weakness;

    frequency unknown: rhabdomyolysis.

    From the nervous system:

    often: headache, dizziness, insomnia;

    infrequently: nervousness, paresthesia,peripheral neuropathy, tremor, migraine, fainting, anxiety, anxiety disorder (excessive, uncontrolled and often irrational anxiety about everyday events), panic disorder panic attacks), confusion, depression, nightmarish dreams, sleep disturbance, drowsiness, memory impairment.

    From the genitourinary system: often: renal dysfunction, kidney failure; infrequently: nocturia, frequent urination, urinary tract infections.

    On the part of the reproductive system:

    infrequently: decreased libido, erectile dysfunction / impotence.

    From the respiratory system: often: cough, upper respiratory tract infections, nasal congestion, sinusitis, violation of upper airway patency;

    infrequently: a feeling of discomfort in the pharynx, pharyngitis, laryngitis, dyspnea, bronchitis, epistaxis, rhinitis, congestion in the respiratory tract.

    From the skin:

    infrequently: alopecia, dermatitis, dry skin, erythema, sensation of "hot flashes" blood to the skin of the face, photosensitivity, itchy skin, skin rash, urticaria, increased sweating.

    Other:

    often: asthenia, increased fatigue, anorexia;

    infrequently: swelling of the face, swelling, fever; frequency unknown: influenza-like symptoms, malaise.

    Laboratory indicators:

    often: hyperkalemia, insignificant reduction of hemoglobin and hematocrit, hypoglycemia;

    infrequently: a slight increase Serum concentrations of urea and creatinine;

    very rarely: increased activity "hepatic" enzymes and bilirubin concentration in plasma blood;

    frequency unknown: hyponatremia.

    Hydrochlorothiazide

    From the hematopoiesis:

    infrequently: agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, purpura, thrombocytopenia.

    Allergic reactions:

    rarely: anaphylactic reaction.

    From the side of metabolism:

    infrequently: anorexia, hyperglycemia, hyperuricemia, hypokalemia, hyponatremia.

    From the nervous system:

    often: headache;

    infrequently: insomnia.

    From the sense organs:

    infrequently: transitory violation visual perception, xantopsy;

    frequency unknown: acute myopia and acute closed angle glaucoma.

    From the side of cardiovascular system:

    infrequently: necrotizing angiitis (vasculitis, cutaneous vasculitis).

    From the respiratory system:

    infrequently: respiratory distress syndrome, including pneumonitis and pulmonary edema.

    From the digestive system:

    infrequently: sialadenitis, spasm, irritation stomach, nausea, vomiting, diarrhea, constipation, jaundice (intrahepatic cholestasis), pancreatitis.

    From the skin:

    infrequently: photosensitivity, urticaria, toxic epidermal necrolysis.

    From the side of the locomotor system apparatus:

    infrequently: muscle cramps.

    From the genitourinary system:

    infrequently: glucosuria, interstitial

    nephritis. impaired renal function, renal insufficiency.

    Other:

    infrequently: fever, dizziness.

    Overdose:Lorista® H

    Information on combination overdose hydrochlorothiazide / losartan no.

    Treatment: symptomatic and maintenance therapy. It is necessary to cancel the drug Lorist® N and carefully monitor the patient. If necessary: ​​induce vomiting (if the patient has recently taken the drug), make up for the BCC, correction of water-electrolyte metabolism disorders and pronounced BP reduction.

    Losartan (data are limited)

    Symptoms: marked decrease in blood pressure, tachycardia, bradycardia due to parasympathetic (vagal) stimulation.

    Treatment: symptomatic therapy, hemodialysis is ineffective.

    Hydrochlorothiazide

    Symptoms: most frequent symptoms are: hypokalemia, hypochloraemia, hyponatremia and Dehydration, as a result of excessive diuresis. With the simultaneous administration of cardiac glycosides, hypokalemia can aggravate the course of arrhythmias.

    Treatment: symptomatic.

    Interaction:

    Simultaneous application with aliskirenom in patients with diabetes mellitus or impaired function kidney (KK less than 60 ml / min) it is contraindicated.

    Losartan

    Rifampicin and fluconazole decreased the concentration of the active metabolite. The clinical significance of this interaction has not been studied. The simultaneous use of losartan, as well as other drugs that affect RAAS, with potassium-sparing diuretics (spironolactone, triamterene, amiloride, eplerenone), potassium preparations or salt substitutes containing potassium, may lead to an increase in serum potassium content. Simultaneous use is not recommended.

    It is possible to reduce the elimination of lithium ions. Therefore, with the simultaneous use of APA II with lithium salts Serum concentrations of lithium should be carefully monitored. With the simultaneous use of ARA II with non-steroidal anti-inflammatory drugs (NSAIDs) (for example, selective cyclooxygenase (COX) -2 inhibitors and non-selective NSAIDs, acetylsalicylic acid in doses that have an anti-inflammatory effect) possibly reducing antihypertensive effect. Simultaneous application of APA II or diuretics with NSAIDs is accompanied by an increased risk of developing renal dysfunction, including the development of acute renal disease deficiency, and an increase in serum potassium content (especially in patients with an existing history of renal dysfunction). At the same time, it should be used with NSAIDs with caution, especially in elderly patients. In this case, it is necessary to adequately fill the BCC and periodically monitor the function of the kidneys from the start of therapy and in the future.

    In some patients with impaired renal function using NSAIDs, including selective COX-2 inhibitors, the simultaneous use of APA II can cause further reversible impairment of renal function.

    Double blockade of RAAS: a double blockade of the RAAS, i.e.,the addition of an ACE inhibitor to APA II therapy is only possible in selected cases under close monitoring of renal function. In patients with atherosclerosis, heart failure or diabetes with target organ damage, double blockade of RAAS (with simultaneous use of ARA II and ACE inhibitors) is accompanied by an increased incidence of arterial hypotension, fainting, hyperkalemia and renal dysfunction (including acute renal failure) in patients with atherosclerosis, heart failure or diabetes mellitus. compared with the use of the drug of one of the groups listed. When used simultaneously with other drugs that cause arterial hypotension, including tricyclic antidepressants, antipsychotics (neuroleptics), baclofen, amifostine the risk of developing arterial hypotension increases.

    Hydrochlorothiazide

    Ethanol, Barbiturates, general anesthetics or antidepressants: may potentiate the risk of developing orthostatic hypotension. Hypoglycemic agents for ingestion and insulin: it may be necessary to correct the dose of hypoglycemic agents, since hydrochlorothiazide affects glucose tolerance.

    Metformin should be used with caution in connection with the risk of developing lactic acidosis against a background of kidney damage caused by hydrochlorothiazide.

    Other antihypertensives: additive action.

    Kolestyramine and colestipol: the absorption of hydrochlorothiazide decreases.

    Colestramine and colestipol in a single dose bind hydrochlorothiazide and reduce its absorption in the gastrointestinal tract (GIT) by 85% and 43%, respectively. Corticosteroids, adrenocorticotropic hormone (ACTH): a marked decrease in the electrolyte content, especially hypokalemia.

    Pressor amines (e.g., epinephrine and norepinephrine): perhaps a slight decrease in the response to the introduction of pressor amines, but not excluding the possibility of their use.

    Non-depolarizing muscle relaxants (e.g., tubocurarine): it is possible to enhance the effect of muscle relaxants.

    Lithium: it is possible to reduce renal clearance of lithium and, accordingly, the risk of lithium intoxication. Therefore, simultaneous use is not recommended.

    Medications, used to treat gout (probenecid, sulfinpirazone and allopurinol): may need to adjust the dose of uricosuric drugs, since hydrochlorothiazide may cause an increase in serum uric acid concentration. Thiazide diuretics can increase the frequency of reactions hypersensitivity to allopurinol.

    Anticholinergic drugs (eg, atropine, biperidene): increase the bioavailability of thiazide diuretics due to a decrease in gastrointestinal motility.

    Cytostatic drugs, for example, cyclophosphamide, methotrexate: increases mielopodavlivayuschee action due to slower excretion from the body.

    Salicylates: when used simultaneously with salicylates (for example, acetylsalicylic acid) in high doses, it is possible to increase their toxic effect on the central nervous system.

    Methyldopa: individual cases of hemolytic anemia are described. simultaneous application. Simultaneous application cyclosporine increases the risk of hyperuricemia and exacerbation of gout.

    Cardiac glycosides: hypokalemia and hypomagnesemia caused by the use of thiazide diuretics, increase the risk of arrhythmias in the treatment of cardiac glycosides.

    Drugs that can cause side effects when the serum potassium content is changed: it is recommended to periodically monitor the potassium content in the blood serum and ECG with simultaneous use with cardiac glycosides and preparations, extending the interval QT (risk of developing ventricular tachycardia such as "pirouette"):

    - I A class of antiarrhythmic drugs (for example, quinidine, disopyramide);

    - III class of antiarrhythmic agents (eg, amiodarone, sotalol, dofetilide);

    - some antipsychotics (for example, thioridazine, chlorpromazine, levomepromazine, trifluoperazine, sulpiride, amisulpride, tiapride, haloperidol, droperidol);

    - other drugs (eg, cisapride, dipemanyl methyl sulfate, erythromycin for intravenous administration, halofantrine, ketanserin, misolastine, sparfloxacin, terfenadine, wincamine for intravenous administration).

    Vitamin D and calcium salts: simultaneous use of thiazide diuretics with vitamin D or calcium salts increases the calcium content in the blood serum, because the excretion of calcium decreases.If you need calcium or vitamin D, you should monitor the calcium level in the blood serum and, possibly, adjust the dose of these drugs.

    Carbamazepine: risk of development symptomatic hyponatremia.

    Need to monitor AD, clinical signs of disturbance of water-electrolyte metabolism. Serum contents should also be monitored periodically electrolytes.

    Hydrochlorothiazide may increase the risk of developing acute renal disease deficiency, especially with the simultaneous use of high doses iodine containing contrast agents. Before their application it is necessary to restore BCC.

    Amphotericin B (for intravenous administration), laxative stimulant or ammonium glycyrrhizinate (contained in licorice): hydrochlorothiazide can enhance violations of water-electrolyte balance, especially hypokalemia.

    Non-steroidal anti-inflammatory drugs (NSAIDs)

    NSAIDs (for example, selective inhibitors of COX-2 and nonselective NSAIDs, acetylsalicylic acid in the doses providing anti-inflammatory act) can reduce the diuretic and hypotensive effects of thiazide diuretics.

    Special instructions:

    Losartan

    Angioedema

    Patients with angioedema (face, lips, throat and / or larynx) in history should be careful observation.

    Arterial hypotension and hypovolemia (dehydration)

    In patients with hypovolemia (dehydration) and / or reduced sodium content in blood plasma, background of diuretic therapy, restriction of consumption of table salt, diarrhea or vomiting possible development symptomatic arterial hypotension, especially after taking the first dose of the drug Lorista® H. Before using the drug should be restored bcc and / or sodium content in the blood plasma.

    Violations of the water-electrolyte balance Violations of water-electrolyte balance are often found in patients with impaired renal function, especially against diabetes mellitus. In this regard, it is necessary to carefully monitor the potassium content in blood plasma and QC, especially in patients with heart failure and CC 30-50 ml / min. Simultaneous application with potassium-sparing diuretics, potassium preparations, salt substitutes containing potassium, or other agents that can increase the potassium content in the blood plasma (eg, heparin), is not recommended.

    Impaired liver function

    The concentration of losartan in the blood plasma increases significantly in patients with cirrhosis of the liver, so the drug Lorista®H should use with caution to patients with mild or moderate impairment of liver function.

    Impaired renal function

    Possible development of renal dysfunction, including renal function insufficiency inhibition of RAAS (especially in patients whose renal function depends on RAAS, for example, with severe heart failure or renal dysfunction in a history).

    Stenosis of the renal artery

    In patients with bilateral renal artery stenosis, as well as stenosis of the artery of a single functioning kidney, preparations that affect RAAS, including APA II, can reversibly increase urea and creatinine concentrations in the blood plasma. Losartan should be used with caution in patients with bilateral stenosis of the renal arteries or stenosis of the artery of a single kidney.

    Kidney Transplantation

    The experience of using Lorist® H in patients who have recently undergone kidney transplantation is absent.

    Primary hyperaldosteronism

    Patients with primary hyperaldosteronism are resistant to antihypertensive drugs that affect RAAS, so such patients are not recommended for using Lorista® H.

    Ischemic heart disease (CHD) and cerebrovascular disease

    As with any antihypertensive drug, an excessive reduction in blood pressure in patients with ischemic heart disease or cerebrovascular disease can lead to the development of myocardial infarction or stroke.

    Heart failure

    In patients whose renal function depends on the state of RAAS (for example, with CHF III-IV functional class by classification NYHA, accompanied or not accompanied by impaired renal function), therapy with drugs that affect RAAS, can be accompanied by severe arterial hypotension, oliguria and / or progressive azotemia, in rare cases - acute renal failure. It is impossible to exclude the development of these disorders due to the suppression of RAAS activity against the background of taking ARA II.

    Stenosis of aortic and / or mitral valves, GOKMP

    The drug Lorista® H, like other vasodilators, is necessary with use caution in patients with hemodynamically significant stenosis of the aortic and / or mitral valves, or with GOKMP.

    Ethnic Features

    Lozartan (as well as other drugs that affect RAAS) has a less pronounced hypotensive effect in patients of the Negroid race compared with representatives of other races, possibly due to a higher incidence of giporenemia in these patients with hypertension.

    Hydrochlorothiazide

    Arterial hypotension and disturbance of water-electrolyte metabolism

    It is necessary to monitor blood pressure, clinical signs of disturbance of water-electrolyte metabolism, in t. h. dehydration, hyponatremia, hypochloraemic alkalosis, hypomagnesemia or hypokalemia, which can develop against a background of diarrhea or vomiting. Periodically monitor the serum content of electrolytes.

    Metabolic and endocrine effects

    Caution is needed in all patients receiving treatment with hypoglycemic agents for ingestion or insulin, since hydrochlorothiazide can weaken their action. Against the background of therapy with thiazide diuretics, latent diabetes mellitus can to manifest.

    Thiazide diuretics, including hydrochlorothiazide, can cause a disturbance of the water-electrolyte balance (hypercalcemia, hypokalemia, hyponatremia, hypomagnesemia and hypokalemic alkalosis).

    Thiazide diuretics can reduce the excretion of calcium by the kidneys and cause a temporary and insignificant increase in the calcium content in the blood plasma. Expressed hypercalcemia may be a sign of latent hyperparathyroidism. Before the study of the function of parathyroid glands, thiazide diuretics should be discontinued. Against the background of treatment with thiazide diuretics, it is possible to increase the concentration of cholesterol and triglycerides in the blood serum.

    Therapy with thiazide diuretics in some patients may exacerbate hyperuricemia and / or aggravate the course of gout.

    Losartan reduces the concentration of uric acid in the blood plasma, so its use in combination with hydrochlorothiazide neutralizes Hyperuricemia caused by a thiazide diuretic.

    Impaired liver function

    Thiazide diuretics should be used with caution in patients with impaired liver function or progressive liver disease, since they can cause intrahepatic cholestasis, and even minimal disturbances in the water-electrolyte balance can to promote the development of the hepatic coma.

    The drug Lorista® N is contraindicated in patients with severe liver dysfunction. there is no experience of using the drug in this category of patients.

    Acute myopia and secondary acute closed-angle glaucoma

    Hydrochlorothiazide is a sulfonamide that can cause idiosyncratic reaction, leading to the development of transient acute myopia and acute closed-angle glaucoma. Symptoms include: sudden reduction in visual acuity or eye pain, which usually appears within a few hours or weeks of initiating hydrochlorothiazide therapy. In the absence of treatment, acute closed-angle glaucoma can lead to persistent loss of vision. Treatment: stop hydrochlorothiazide as soon as possible. If intraocular pressure remains uncontrolled, immediate medical treatment or surgery may be required.Risk factors for the development of acute closed-angle glaucoma are: an allergic reaction to sulfonamide or benzylpenicillin in the anamnesis.

    Are common

    In patients taking thiazide diuretics, reactions Hypersensitivity can develop both in the presence and in the absence of an anamnesis of an allergic reaction or bronchial asthma, but more likely if there are any in the history. There are reports of an exacerbation of the systemic lupus erythematosus with the use of thiazide diuretics.

    Special information on auxiliary substances

    The drug Lorista® H contains lactose, therefore the drug is contraindicated in patients with lactase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome.

    Effect on the ability to drive transp. cf. and fur:
    At the beginning of therapy, the drug Lorista® H can cause a decrease in blood pressure, dizziness or drowsiness, thus indirectly affect the psychoemotional state. For safety reasons, before starting activities requiring increased attention, patients should first assess their response to ongoing treatment.
    Form release / dosage:
    Tablets, film-coated, 12.5 mg + 50 mg.
    Packaging:

    By 7, 10 or 14 tablets in a blister (contour mesh packaging) from the combined material PVC / PVDC - foil aluminum.

    For 2, 4, 8, 12 or 14 blisters (contour cell packs) of 7 tablets), or 3, 6 or 9 blisters (contour cell packs) of 10 tablets), or 1, 2, 4, 6 or 7 blisters (contour cell packs) of 14 tablets), together with instructions for use, are placed in a cardboard package.

    Storage conditions:At a temperature of no higher than 25 ° C, in the original packaging. Keep out of the reach of children.
    Shelf life:

    5 years.

    Do not use the drug after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-001564/08
    Date of registration:14.03.2008 / 01.10.2013
    Expiration Date:Unlimited
    The owner of the registration certificate:KRKA, dd, Novo mesto, AOKRKA, dd, Novo mesto, AO
    Manufacturer: & nbsp
    KRKA, d.d. Slovenia
    Representation: & nbspKRKA, dd, Novo mesto, AOKRKA, dd, Novo mesto, AO
    Information update date: & nbsp19.03.2018
    Illustrated instructions
      Instructions
      Up